The Transdermal Scopolamine Market has been analyzed to grow during the research period from 2017 to 2025.
What Are the Driving Factors for Transdermal Scopolamine Market?
- Growing number of surgical procedures occurring per year globally
- Increasing awareness about the benefits of the transdermal scopolamine patches
|By Regions||North America, Asia-Pacific, Europe, Middle East & Africa and Latin America|
|England||GlaxoSmithKline Plc & others|
|The U.S.||Baxter International, Inc., Perrigo Company Plc & others|
|Switzerland||Novartis International AG & others|
|South Korea||Myungmoon Pharma Co. LTD. & others|
Why Buy this Report?
- The report provides in-depth analysis of market determinant factors.
- It analyzes market dynamics for each segment (such as Regions).
- It provides 8 years forecast by analyzing push and pull factors affecting the dynamics of the market.
- This research report provides application level cross-sectional analysis for each product type.
- This report provides regional level pricing trend analysis.
- This Analysis acts as business decision support system by analyzing key trends in each market segment.
- This market report provides insights regarding business strategies of leading market players.
Transdermal Scopolamine Market - Introduction
The global transdermal scopolamine market is expected to grow at a fast pace during the forecast period 2017 to 2025. In the transdermal scopolamine market report, the market is segmented based on region. Scopolamine is primarily used for the treatment of motion sickness and postoperative nausea and vomiting, apart from treatment of seasickness, irritable bowel syndrome and eye inflammation among others. Scopolamine was first used in 1947 and is obtained from Scopolia, a type of nightshade plant variant. Scopolamine can be administered by various routes, such as transdermal, rectal, buccal, subcutaneous, sublingual, intramuscular and intravenous among others. Transdermal route of scopolamine administration is one of the most popular and is considered to be a very convenient mode of self-administration by the patients. The transdermal scopolamine market size and volume is primarily being driven by the increasing application for reducing postoperative nausea and vomiting.
|Base Year of Estimation||2016|
|Value Estimation Year||2017|
|Forecast Period||2017 - 2025|
|Market Segmentations||By Regions|
|Regional Scope||North America, Asia-Pacific, Europe, Middle East & Africa and Latin America|
|Report Coverage||Market Dynamics, Segmentation Overview and Competitive Landscape of the market|
The number of surgical procedures occurring per year globally is estimated to have grown by approximately 38% in last 8 years, as per the studies conducted by World Health Organization (WHO) and Organization for Economic Co-operation and Development (OECD). Such widespread growth in the number of surgical procedures has been the primary driver for the transdermal scopolamine market. Prescription of transdermal scopolamine is primarily done for tackling anesthesia induced vomiting and nausea in post-operative patients.
Additionally, transdermal scopolamine patch has been seeing an increasing application in emerging economies. The rate of growth in the number of surgical procedures is much higher in such countries, and owing to the growing awareness regarding the benefits of these transdermal scopolamine patches, the demand has also been increasing at a fast pace. The high level of awareness, regarding the advantages of transdermal scopolamine, in developed nations has also resulted in higher over the counter (OTC) sales of these patches. Such factors have been conjointly boosting the growth of transdermal scopolamine market.
Adverse effects, such as drowsiness and retarded motion among others, and adverse withdrawal symptoms are some of the factors which have been restraining the growth of the transdermal scopolamine market globally. However, the increasing usage of scopolamine patches by various tourists have been instrumental in positively impacting the transdermal scopolamine market growth trends. The increasing rates of awareness and growing rates of surgery in emerging economies are some other factors which are expected to offer good growth opportunities for the transdermal scopolamine market.
By geography, the market has been segmented into Asia-Pacific, North America, Middle East & Africa (MEA), Europe and Latin America. In terms of revenue, North America accounted for the largest market share of the transdermal scopolamine market, followed by Europe. The growth in the total number of surgical procedures, coupled with the high awareness of the benefits offered by transdermal scopolamine patches, are the primary growth drivers for the North American market for transdermal scopolamine. Asia-Pacific is expected to become the second largest market for transdermal scopolamine, by 2025, owing to the fast growth in the prescription for transdermal scopolamine patches.
Transdermal scopolamine market competition is primarily between a few manufacturers, owing to the consolidated nature of the market. Major companies operating in the transdermal scopolamine market are GlaxoSmithKline Plc (England), Baxter International, Inc. (The U.S.), Perrigo Company Plc (The U.S.), Novartis International AG (Switzerland) and Myungmoon Pharma Co. LTD. (South Korea) among others.
|Related Upcoming Report Titles|
|Get Free Samples for Market Research Reports. The privacy and security of your shared information are very important to us. Our website is secure and your personal details are safe.|